---
layout: post
title: "华仁药业：子公司喷他佐辛原料药通过CDE审批"
date: 2022-05-16 19:16:03 +0800
categories: zhengquanshibao
tags: 证券时报新闻
---
<p style="display:none;height:1px;overflow:hidden;"><br /></p><!-- EM_StockImg_Start --><p style="text-align:center;"><a href="http://quote.eastmoney.com/unify/r/0.300110" data-code="300110|0|2" data-code2="300110|0|80|" class="EmImageRemark" target="_blank"><img src="https://webquoteklinepic.eastmoney.com/GetPic.aspx?nid=0.300110&imageType=k&token=28dfeb41d35cc81d84b4664d7c23c49f&at=1" border="0" alt="K图 300110_0" data-code="K 300110|0|2" data-code2="K 300110|0|80|" style="border:#d1d1d1 1px solid;" width="578" height="276" /></a></p><!-- EM_StockImg_End --><p>华仁药业(300110)5月16日晚间公告，公司全资子公司安徽恒星制药提交的“喷他佐辛”原料药注册申请通过了CDE审批，是国内第2家通过喷他佐辛原料药CDE审批的企业。<br /></p><p class="em_media">（文章来源：证券时报）</p>

<http://finews.zning.xyz/html_News/NewsShare.html?infoCode=NW202205162380746716>

[返回证券时报新闻](//finews.withounder.com/category/zhengquanshibao.html)｜[返回首页](//finews.withounder.com/)